...
首页> 外文期刊>Advanced Materials >Supramolecular Nanodiscs Self-Assembled from Non-Ionic Heptamethine Cyanine for Imaging-Cuided Cancer Photothermal Therapy
【24h】

Supramolecular Nanodiscs Self-Assembled from Non-Ionic Heptamethine Cyanine for Imaging-Cuided Cancer Photothermal Therapy

机译:超分子纳米光盘自非离子七甲胺菁自组装的成像线索的光热疗法。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Supramolecular nanomedicines, which use supramolecular design to improve the precision and effectiveness of pharmaceutical practice and optimize pharmacokinetic profiles, have gathered momentum to battle cancer and other incurable diseases, for which traditional small-molecular and macromolecular drugs are less effective. However, the lack of clinical approval of supramolecular assembly-based medicine underscores the challenges facing this field. A 2D nanodisc-based supramolecular structure is formed by a non-ionic heptamethine cyanine (Cy7) dye, which generates fluorescence self-quenching but unique photothermal and photoacoustic properties. These Cy7-based supramolecular nanodiscs exhibit passive tumor-targeting properties to not only visualize the tumor by near-infrared fluorescence imaging and photoacoustic tomography but also induce photothermal tumor ablation under irradiation. Due to the nature of organic small molecule, they induce undetectable acute toxicity in mice and can be eliminated by the liver without extrahepatic metabolism. These findings suggest that the self-assembling cyanine discs represent a new paradigm in drug delivery as single-component supramolecular nanomedicines that are self-delivering and self-formulating, and provide a platform technology for synergistic clinical cancer imaging and therapy.
机译:超分子纳米药物使用超分子设计来提高药学实践的准确性和有效性,并优化药代动力学特征,已聚集势头与癌症和其他不可治愈的疾病作斗争,而传统的小分子和大分子药物效果较差。然而,基于超分子组装的药物的临床批准缺乏强调了该领域面临的挑战。一种基于2D纳米光盘的超分子结构是由非离子型庚甲基花青(Cy7)染料形成的,该染料产生荧光自猝灭但具有独特的光热和光声特性。这些基于Cy7的超分子纳米碟片具有被动的肿瘤靶向特性,不仅可以通过近红外荧光成像和光声层析成像来可视化肿瘤,还可以在照射下诱导光热消融。由于有机小分子的性质,它们会在小鼠中诱发无法检测到的急性毒性,并且可以被肝脏清除而无需肝外代谢。这些发现表明,自组装的花菁圆盘代表了药物递送的一个新范例,即单组分超分子纳米药物具有自我递送和自我形成的特性,并为临床临床协同成像和治疗提供了平台技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号